Jeffrey Eisele's most recent trade in Apellis Pharmaceuticals Inc was a trade of 278 Common Stock done at an average price of $29.5 . Disclosure was reported to the exchange on Jan. 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 29.53 per share. | 29 Jan 2025 | 278 | 55,312 (0%) | 0% | 29.5 | 8,208 | Common Stock |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 1,291 | 55,590 (0%) | 0% | 30.4 | 39,279 | Common Stock |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 264 | 56,881 (0%) | 0% | 28.7 | 7,577 | Common Stock |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 23 Dec 2024 | 63 | 57,145 (0%) | 0% | 33.1 | 2,085 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 29 Jan 2024 | 971 | 57,208 (0%) | 0% | 65.5 | 63,630 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 29 Jan 2024 | 279 | 58,179 (0%) | 0% | 64.1 | 17,895 | Common Stock | |
| Apellis Pharmaceuticals Inc | Eisele Jeffrey | Chief Development Officer | 23 Jan 2024 | 7,378 | 58,458 (0%) | 0% | 63.7 | 469,905 | Common Stock | |
| Apellis Pharmaceuticals Inc | Eisele Jeffrey | Chief Development Officer | 22 Jan 2024 | 1,607 | 65,836 (0%) | 0% | 65.0 | 104,449 | Common Stock | |
| Apellis Pharmaceuticals Inc | Eisele Jeffrey | Chief Development Officer | 17 Jan 2024 | 5,207 | 67,443 (0%) | 0% | 65.6 | 341,475 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 16 Jan 2024 | 28,367 | 28,367 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 16 Jan 2024 | 19,508 | 73,088 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Eisele Jeffrey | Chief Development Officer | 16 Jan 2024 | 438 | 72,650 (0%) | 0% | 66.8 | 29,262 | Common Stock | |
| Apellis Pharmaceuticals Inc | Eisele Jeffrey | Chief Development Officer | 26 Dec 2023 | 235 | 53,580 (0%) | 0% | 60.2 | 14,154 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 26 Dec 2023 | 68 | 53,815 (0%) | 0% | 57.9 | 3,935 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 23 Feb 2023 | 1,646 | 53,883 (0%) | 0% | 68.8 | 113,179 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 21 Feb 2023 | 14,023 | 14,023 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 21 Feb 2023 | 9,886 | 56,354 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 21 Feb 2023 | 825 | 55,529 (0%) | 0% | 58.5 | 48,263 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 30 Jan 2023 | 883 | 46,468 (0%) | 0% | 52.8 | 46,587 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 27 Jan 2023 | 367 | 47,351 (0%) | 0% | 52.8 | 19,367 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 23 Jan 2023 | 4,479 | 47,718 (0%) | 0% | 51.6 | 231,027 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 20 Jan 2023 | 2,033 | 52,197 (0%) | 0% | 52.1 | 105,818 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 12 Jan 2023 | 35,472 | 35,472 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Chief Development Officer | 12 Jan 2023 | 22,580 | 54,230 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 25 Apr 2022 | 1,250 | 31,739 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 25 Apr 2022 | 89 | 31,650 (0%) | 0% | 51.7 | 4,600 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 28 Jan 2022 | 434 | 32,989 (0%) | 0% | 38.6 | 16,748 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 21 Jan 2022 | 36,951 | 36,951 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 21 Jan 2022 | 26,051 | 33,423 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 22 Dec 2021 | 89 | 7,372 (0%) | 0% | 47.8 | 4,256 | Common Stock | |
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 01 Mar 2021 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 01 Mar 2021 | 1,250 | 7,461 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 28 Jan 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 28 Jan 2021 | 5,000 | 6,211 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Jeffrey Eisele | Exec VP, Program Team Lead | 23 Dec 2020 | 1,211 | 1,211 (0%) | 0% | 0 | Common Stock |